A special purpose acquisition company (SPAC) sponsored by Liang Meng, founding managing partner of China’s Ascendent Capital Partners, has raised $300 million for global consumer technology investments.
The Singapore Exchange (SGX) will consider allowing listings by special purpose acquisition companies (SPACs) on the back of a spike in fundraising activity for these structures in the US.
Primavera Capital Group has joined the trickle of Asia-based private equity investors launching special purpose acquisition companies (SPACs) in the US, targeting a $300 million capital raise for consumer deals.
Peter Thiel (pictured), co-founder of PayPal, Palantir Technologies and Founders Fund, and Richard Li, son of Hong Kong billionaire Li Ka-shing, are launching another special purpose acquisition vehicle (SPAC) that will target new economy assets in Southeast...
Relx Technology, a Chinese e-cigarette producer backed by Source Code Capital and Sequoia Capital China, has filed for an IPO in the US.
Japanese financial technology start-up WealthNavi gained 100% on its trading debut following a JPY17.9 billion ($172.9 million) IPO that facilitated partial exits for Gree Ventures, Infinity Venture Partners, and Global Brain.
The coronavirus pandemic has played havoc with Asian private equity, contributing to a resurgence in IPOs, increased bifurcation in fundraising, a rush for healthcare, and a generally staggered revival
Pop Mart International Group, China’s largest fashion toy retailer, gained 79% on its Hong Kong trading debut following a HK$5.22 billion ($674 million) IPO.
Harbour BioMed, a Chinese drug developer backed by the likes of Advantech Capital, Legend Capital and GIC, raised HK$1.71 billion ($221 million) through a Hong Kong IPO.
Australian public market investors are famously unforgiving of private equity when IPOs fail to perform. The markets are open for business again, but how long will the golden period last?
The Indian franchise of US fast food giant Burger King will launch its IPO this week seeking to raise up to INR8.1 billion ($109.5 million), facilitating a partial exit for majority shareholder Everstone Group.
Silk Laser Clinics, an Australia-based cosmetic treatments business, is looking to raise A$83.4 million ($61.5 million) through a domestic IPO, which will facilitate a partial exit for majority owner Advent Partners.
JD Health, a Chinese online-to-offline healthcare business that raised around $1.9 billion from private investors after it spun out from JD.com, is looking to raise HK$26.9 billion ($3.48 billion) in its Hong Kong IPO.
Warburg Pincus has agreed to make another partial exit from ESR, the pan-Asian logistics real estate platform it established in 2011 and took public last year, which will see its stake fall to 4.56%.
Wish, a cross-border e-commerce platform that connects Chinese merchants who primarily sell products through domestic channels like Alibaba Group’s Taobao and Tmall with consumers in the US and Europe, has filed for a US IPO.
Antengene, a China-based drug developer that previously raised $238 million across three private funding rounds, closed roughly flat on its first day of trading in Hong Kong following a HK$2.78 billion ($359 million) IPO.
Yatsen Holding, the parent company of Chinese cosmetics brand Perfect Diary, gained 75% on its first day of trading on the New York Stock Exchange following a $616.9 million IPO.
Macquarie and Armitage Associates are both set to make partial exits when analytics software provider Nuix completes its Australia IPO.
Warburg Pincus and Advantage Partners triumphed in the firm of the year categories at the 2020 AVCJ Private Equity & Venture Capital Awards, with The Carlyle Group and Affinity Equity Partners also among the winners with two trophies apiece.
17 Education & Technology Group, a China-based education service provider that claims to pursue an integrated “in-school plus after-school” model, has filed for a US IPO.
Kuaishou, a Chinese video sharing and social networking platform backed by the likes of Tencent Holdings, Sequoia Capital China, Boyu Capital and DST Global, has filed for a Hong Kong IPO.
JW Therapeutics, a private equity-backed Chinese drug developer specializing in CAR T-cell therapies that engineer immune cells to fight cancers, has raised HK$2.33 billion ($300 million) through a Hong Kong IPO.
Yatsen Holding, the parent company of Chinese cosmetics brand Perfect Diary has filed for a US IPO, potentially delivering a liquidity event for the likes of Hillhouse Capital, ZhenFund and Gaorong Capital.
Private equity-backed Ant Group’s bumper IPO in Hong Kong and Shanghai has been put on hold by Chinese regulators over a potential failure to meet listing qualifications or disclosure requirements.